Skip to main content

Specialty Pharmacy

  • Impax Labs looks to market generic cancer pain drug

    HAYWARD, Calif. — Drug maker Impax Labs is looking to challenge the patent protection on a drug used to treat pain related to cancer, the company said Monday.

    Impax said it had filed a regulatory approval application with the Food and Drug Administration for a generic version of Cephalon's Fentora (fentanyl) buccal tablets in the 100 mcg, 200 mcg, 400 mcg, 600 mcg and 800 mcg strengths. The drug is used to treat breakthrough cancer pain, defined as pain related to cancer that can't be controlled by other drugs.

  • MedPro Rx makes Triangle Business Journal's fast-growing companies list

    RALEIGH, N.C. — The Triangle Business Journal has named MedPro Rx to its list of the fastest-growing companies in the North Carolina Research Triangle for the fourth consecutive year, the specialty pharmacy provider said Monday.

    MedPro Rx said it had ranked No. 28 on the journal's 2011 Fast 50 Award list, evaluated by PricewaterhouseCoopers. The company ranked No. 1 in 2008, No. 5 in 2009 and No. 16 in 2010.

  • FDA approves Eylea

    SILVER SPRING, Md. — After being unanimously recommended for approval by a Food and Drug Administration panel, the FDA has approved an eye disorder treatment created by Regeneron Pharmaceuticals.

  • FDA revokes breast cancer approval for Avastin

    SILVER SPRING, Md. — A drug widely used to treat breast cancer is not safe or effective, the Food and Drug Administration said Friday.

  • FDA approves Erwinaze for acute lymphoblastic leukemia

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new chemotherapy drug for treating acute lymphoblastic leukemia, the agency said Friday.

    The FDA announced the approval of EUSA Pharma's Erwinaze (asparaginase Erwinia chrysanthemi) to treat patients with ALL who have developed an allergy to E. coli-derived asparaginase and pegaspargase chemotherapy drugs.

  • Former Mercer executive named president of CVS Caremark's Accordant business

    WOONSOCKET, R.I. — CVS Caremark has appointed Kevin Murphy president for Accordant Health Services, a CVS Caremark company that provides disease management and case management services for people with rare chronic conditions.

    Murphy is in charge of integrating the company's leading rare disease management programs with its specialty pharmacy programs and new focus on medical pharmacy management.

  • Need for more convenient therapies, competition from generics, biosimilars spurs RA drug development

    MOUNTAIN VIEW, Calif. — The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

  • FDA approves drug for rare bone marrow disorder

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a rare bone marrow disease, the agency said Wednesday.

X
This ad will auto-close in 10 seconds